The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

Uptake of lecanemab (Leqembi), a monoclonal antibody approved to treat early Alzheimer's disease, appeared to be marked by ...

The U.S. Food and Drug Administration said on Friday it had cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's ...

The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients ...

Most ARIA cases were asymptomatic and radiographically mild. Treating early Alzheimer's disease patients with lecanemab (Leqembi) was feasible and most patients tolerated the drug well ...

Leqembi, produced by Eisai and Biogen, is not a cure for Alzheimer’s but significantly slows down cognitive decline. It ...

Explore why INmune Bio, Inc. is a speculative Strong Buy for high-risk investors. Click for the upcoming catalysts that make ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

More than 80,000 Kentuckians aged 65 and older live with an Alzheimer’s diagnosis as reported in the 2025 Alzheimer’s Disease ...

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 ...